DSIJ Mindshare

MF Risk Measures: When Less Is More

The next time that you select a fund, remember that less risk not only means less pain but more gain also. The article explains the how and why of this theory

Ninad Ramdasi 0 756 Article rating: 4.8

The next time that you select a fund, remember that less risk not only means less pain but more gain also. The article explains the how and why of this theory

Cipla receives final approval for its abbreviated new drug application

Cipla’s Difluprednate Ophthalmic Emulsion 0.05 per cent is an AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol®. 

Armaan Madhani 0 936 Article rating: 3.6

Pharmaceutical major Cipla has received final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05 per cent) from United States Food & Drug Administration (US FDA). 

RSS
First27742775277627772779278127822783Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR